Human Papillomavirus (HPV) vaccination coverage among French adolescents: A claims data study

被引:1
|
作者
de Pouvourville, G. [1 ]
Guyot, E. [2 ]
Farge, G. [3 ]
Belhassen, M. [2 ]
Berard, M. [2 ]
Jacoud, F. [2 ]
Bensimon, L. [3 ]
Baldauf, J. J. [4 ]
机构
[1] ESSEC Business Sch, 3 Ave Bernard Hirsch,CS 50105 Cergy, F-95021 Cergy Pontoise, France
[2] PELyon, 210 Ave Jean Jaures, F-69007 Lyon, France
[3] MSD France, 10-12 Cr Michelet, F-92800 Puteaux La Defense, France
[4] Univ Hosp Strasbourg, Ave Moliere, F-67200 Strasbourg, France
关键词
Human papillomavirus; Vaccination coverage rate; Claims database; Full vaccination; Partial vaccination; FRANCE; POPULATION; CANCER;
D O I
10.1016/j.vaccine.2024.06.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The French cancer control strategy 2021-2030 aims to achieve 80 % human papillomavirus (HPV) vaccination coverage. Since 2021, HPV vaccination is also recommended for boys aged 11-14 years, with a catch-up vaccination recommended for unvaccinated adolescents aged <= 19 years. The PAPILLON study used claims data to monitor the evolution of HPV Vaccination Coverage Rate (VCR) in the French population. Methods: The annual HPV VCR was described from 2017 to 2022. Partial vaccination was defined as the dispensing of at least one dose of HPV vaccination. Full scheme vaccination was defined according to the current French recommendations as two or three doses of HPV vaccine over an 18-month period. Annual HPV vaccine initiation rates were estimated on 11-14 and 15-19-year-olds adolescents. Cumulative VCR were estimated on adolescents aged between 11 and 19 years at the time of first vaccination. Results: Overall, 1,773,900 females and 592,167 males initiated HPV vaccination between 2017 and 2022. Initiations occurred between 11 and 14 years for 67.3 % of females and 62.4 % of males with a median time between the first two doses of 195 days and 190 days, respectively. In girls, the cumulative vaccination rate for the partial scheme vaccination at 15 y.o. increased from 28.1 % in 2017 to 50.9% in 2022. Similarly, the cumulative vaccination rate for the full scheme vaccination at 16 y.o. increased from 15.5 % in 2017 to 33.8 % in 2022. In 2022, the initiation rates for males were 12.6 % at age 14 and 1.9 % at age 19. Conclusions: HPV vaccination coverage increased between 2017 and 2022 among girls targeted by the recommendation but remains insufficient. The results of this study show a tentative but promising start to vaccination in boys. This study will monitor the effects of actions taken to improve vaccination, including the extension of vaccination competencies to community pharmacists since end of 2022.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Human papillomavirus vaccination - Glimpse into the black box of HPV vaccination
    English, Peter M.
    Neal, Keith
    BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 (7664):
  • [42] Issues in Human Papillomavirus Vaccination in Adolescents
    Moscicki, Anna-Barbara
    Smith, Jennifer S.
    JOURNAL OF ADOLESCENT HEALTH, 2008, 43 (04) : S1 - S4
  • [43] An Integrative Review of the Influence on Human Papillomavirus Vaccination Adherence among Adolescents
    Shin, Hyewon
    Choi, Sunyeob
    Lee, Ju-Young
    HEALTHCARE, 2023, 11 (18)
  • [44] Understanding the factors affecting human papillomavirus vaccination acceptance among adolescents
    Mammas, Ioannis
    Sourvinos, George
    Theodoridou, Maria
    Spandidos, Demetrios A.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2015, 36 : S90 - S90
  • [45] Human papillomavirus infection among young adolescents in India: Impact of vaccination
    Hussain, Showket
    Bharadwaj, Mausumi
    Nasare, Vilas
    Kumari, Malasha
    Sharma, Shashi
    Hedau, Suresh
    Das, Bhudev C.
    JOURNAL OF MEDICAL VIROLOGY, 2012, 84 (02) : 298 - 305
  • [46] Vaccination against human papillomavirus in adolescents
    Hillemanns, R
    Dürst, M
    MONATSSCHRIFT KINDERHEILKUNDE, 2005, 153 (09) : 824 - +
  • [47] Human Papillomavirus Vaccination: What Are the Reasons for Nonvaccination Among US Adolescents?
    Thompson, Erika L.
    Rosen, Brittany L.
    Vamos, Cheryl A.
    Kadono, Mika
    Daley, Ellen M.
    JOURNAL OF ADOLESCENT HEALTH, 2017, 61 (03) : 288 - 293
  • [48] Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination
    Lehtinen, Tuomas
    Soderlund-Strand, Anna
    Petaja, Tiina
    Eriksson, Tiina
    Jokiranta, Sakari
    Natunen, Kari
    Dillner, Joakim
    Lehtinen, Matti
    JOURNAL OF INFECTIOUS DISEASES, 2017, 216 (08): : 966 - 968
  • [49] Human Papillomavirus (HPV) Vaccine Uptake and the Willingness to Receive the HPV Vaccination among Female College Students in China: A Multicenter Study
    You, Dingyun
    Han, Liyuan
    Li, Lian
    Hu, Jingcen
    Zimet, Gregory D.
    Alias, Haridah
    Danaee, Mahmoud
    Cai, Le
    Zeng, Fangfang
    Wong, Li Ping
    VACCINES, 2020, 8 (01)
  • [50] Impact of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the US
    Gillison, Maura L.
    Broutian, Tatevik
    Graubard, Barry
    Pickard, Robert
    Tong, Zhen-Yue
    Xiao, Weihong
    Kahle, Lisa
    Chaturvedi, Anil
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35